Comparative Pharmacology
Head-to-head clinical analysis: NAFAZAIR versus TRIESENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAFAZAIR versus TRIESENCE.
NAFAZAIR vs TRIESENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown. It is a purified fatty acid derivative that may modulate inflammatory responses.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
2.5 mg subcutaneously once daily.
1 to 4 mg (0.025 to 0.1 mL of 40 mg/mL suspension) intravitreal injection once.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours; in moderate renal impairment (CrCl 30-50 mL/min) extends to 12-15 hours.
Approximately 3.3 hours for triamcinolone acetonide; with intravitreal administration, detectable levels persist for weeks to months.
Primarily renal excretion (70-80% as unchanged drug), with 15-20% fecal elimination via biliary secretion.
Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for minimal clearance.
Category C
Category C
Intranasal Antihistamine/Corticosteroid
Corticosteroid